{"organizations": [], "uuid": "d375c0fa75836439a28a522a1672a94dc5e51e73", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-amicus-therapeutics-sees-fy-2018-r/brief-amicus-therapeutics-sees-fy-2018-revenue-75-million-to-85-million-idUSASB0C7YR", "country": "US", "domain_rank": 408, "title": "BRIEF-Amicus Therapeutics Sees FY 2018 Revenue $75 Million To $85 Million", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.994, "site_type": "news", "published": "2018-02-28T20:10:00.000+02:00", "replies_count": 0, "uuid": "d375c0fa75836439a28a522a1672a94dc5e51e73"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-amicus-therapeutics-sees-fy-2018-r/brief-amicus-therapeutics-sees-fy-2018-revenue-75-million-to-85-million-idUSASB0C7YR", "ord_in_thread": 0, "title": "BRIEF-Amicus Therapeutics Sees FY 2018 Revenue $75 Million To $85 Million", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "amicus therapeutics inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - Amicus Therapeutics Inc:\n* AMICUS THERAPEUTICS ANNOUNCES FULL-YEAR 2017 FINANCIAL RESULTS AND 2018 CORPORATE UPDATES\n* SEES FY 2018 REVENUE $75 MILLION TO $85 MILLION * DEVELOP AND EXPAND PRECLINICAL PIPELINE TO ENSURE AT LEAST ONE NEW CLINICAL PROGRAM IN 2019\n* ON TRACK TO ACHIEVE FY18 REVENUE GUIDANCE OF $75M-$85M\n* REITERATED FULL-YEAR 2018 REVENUE AND NET CASH SPEND GUIDANCE\n* CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED $358.6 MILLION AT DECEMBER 31, 2017\n* FY2018 REVENUE VIEW $86.8 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-28T20:10:00.000+02:00", "crawled": "2018-03-01T21:01:05.000+02:00", "highlightTitle": ""}